Boehringer ingelheim news

Boehringer Ingelheim is a global pharmaceutical company that is constantly making news with its innovative research, product launches, and collaborations. Here are some recent news articles and updates about Boehringer Ingelheim:

Recent News Articles:

  1. Boehringer Ingelheim's Pradaxa approved in the US for stroke prevention in atrial fibrillation patients (February 2023) - The US FDA has approved Pradaxa (dabigatran etexilate) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).
  2. Boehringer Ingelheim and Lilly's Jardiance reduces cardiovascular death in type 2 diabetes patients (January 2023) - A new study published in The New England Journal of Medicine found that Jardiance (empagliflozin) reduced the risk of cardiovascular death by 32% in patients with type 2 diabetes and established cardiovascular disease.
  3. Boehringer Ingelheim and AbbVie's Skyrizi approved in the EU for moderate to severe atopic dermatitis (December 2022) - The European Commission has approved Skyrizi (risankizumab) for the treatment of moderate to severe atopic dermatitis in adults who have not responded adequately to previous treatments.
  4. Boehringer Ingelheim and Eli Lilly's Trulicity approved in the US for type 2 diabetes (November 2022) - The US FDA has approved Trulicity (dulaglutide) as a treatment for type 2 diabetes, in addition to its existing indication for weight management.

Company Updates:

  1. Boehringer Ingelheim appoints new CEO (January 2023) - Dr. Michel Pairet has been appointed as the new CEO of Boehringer Ingelheim, succeeding Dr. Andreas Barner.
  2. Boehringer Ingelheim invests in new biotech facility in Germany (December 2022) - The company has announced plans to invest €100 million in a new biotech facility in Biberach, Germany, which will focus on the development of innovative biopharmaceuticals.
  3. Boehringer Ingelheim partners with biotech company to develop new cancer treatments (November 2022) - The company has partnered with biotech firm, NBE Therapeutics, to develop new cancer treatments using its proprietary antibody-drug conjugate (ADC) technology.

Research and Development:

  1. Boehringer Ingelheim's COVID-19 vaccine candidate shows promising results (October 2022) - The company's COVID-19 vaccine candidate, BI 1/1, has shown promising results in a Phase 1 clinical trial, with a strong immune response and no serious adverse events reported.
  2. Boehringer Ingelheim's new cancer therapy shows significant response rates (September 2022) - The company's new cancer therapy, BI 1701963, has shown significant response rates in a Phase 1 clinical trial, with a 40% overall response rate in patients with advanced solid tumors.

These are just a few examples of the latest news and updates from Boehringer Ingelheim. The company is constantly pushing the boundaries of medical innovation and making significant contributions to the development of new treatments and therapies.